This Article Full Text Full Text (PDF) All Versions of this Article: j.jacc.2007.04.031v1 50/2/119    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jaffe, R. Articles by Strauss, B. H. Search for Related Content PubMed PubMed Citation Articles by Jaffe, R. Articles by Strauss, B. H.

FOCUS ISSUE: DRUG-ELUTING STENTS: STATE-OF-THE-ART PAPER

Late and Very Late Thrombosis of Drug-Eluting Stents

Evolving Concepts and Perspectives

Schulich Heart Program, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada

Manuscript received February 12, 2007; revised manuscript received March 30, 2007, accepted April 2, 2007.

^_* Reprint requests and correspondence: Dr. Bradley H. Strauss, Reichmann Research Chair in Cardiovascular Sciences, Sunnybrook Health Sciences Center, 2075 Bayview Avenue, Suite A-253, Toronto, Ontario, Canada M4N 3M5 (Email: bradley.strauss{at}sunnybrook.ca).

Coronary stents are the mainstay of percutaneous coronary revascularization procedures and have significantly decreased the rates of acute vessel closure and restenosis. Stent thrombosis (ST) after percutaneous coronary intervention is an uncommon and potentially catastrophic event that might manifest as myocardial infarction and sudden death. Optimization of stent implantation and dual antiplatelet therapy have markedly reduced the occurrence of this complication. Bare-metal stent (BMS) thrombosis occurs in <1% of the cases, usually within the first month after implantation. The advent of drug-eluting stents (DES) has raised concerns regarding later occurrence of ST, beyond the traditional 1-month timeframe, especially in complex lesion subsets that were excluded from randomized trials that compared BMS to DES. There is widespread controversy regarding the actual incremental risk associated with DES. Recent studies suggest a 0.5% increased long-term thrombosis risk with DES; however, the clinical significance of these events remains under debate. The degree of protection achieved by dual antiplatelet therapy and optimal duration of treatment are under investigation. Novel stent designs might potentially decrease the incidence of this event. In this review, we will describe the current knowledge of the pathophysiology of late DES thrombosis, although many aspects remain incompletely understood.

Abbreviations and Acronyms   BMS = bare-metal stent(s)   DES = drug-eluting stent(s)   MI = myocardial infarction   PCI = percutaneous coronary intervention   PES = paclitaxel-eluting stent(s)   SES = sirolimus-eluting stent(s)   ST = stent thrombosis

This article has been cited by other articles:

				T. Palmerini, G. Dangas, R. Mehran, A. Caixeta, P. Genereux, M. P. Fahy, K. Xu, E. Cristea, A. J. Lansky, and G. W. Stone Predictors and Implications of Stent Thrombosis in Non-ST-Segment Elevation Acute Coronary Syndromes: The ACUITY Trial Circ Cardiovasc Interv, December 1, 2011; 4(6): 577 - 584. [Abstract] [Full Text] [PDF]

				T. Inoue, K. Croce, T. Morooka, M. Sakuma, K. Node, and D. I. Simon Vascular Inflammation and Repair: Implications for Re-Endothelialization, Restenosis, and Stent Thrombosis J. Am. Coll. Cardiol. Intv., October 1, 2011; 4(10): 1057 - 1066. [Abstract] [Full Text] [PDF]

				A. Yehya and M. K. Mandawat Intravascular Ultrasound: Its Use and Limitations in Cardiac Catheterization Laboratory Cardiac Cath Lab Director, April 1, 2011; 1(2): 67 - 71. [Abstract] [PDF]

				T.-H. Chen and R. Matyal The Management of Antiplatelet Therapy in Patients With Coronary Stents Undergoing Noncardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2010; 14(4): 256 - 273. [Abstract] [PDF]

				G. Niccoli, R. A. Montone, G. Ferrante, and F. Crea The Evolving Role of Inflammatory Biomarkers in Risk Assessment After Stent Implantation J. Am. Coll. Cardiol., November 23, 2010; 56(22): 1783 - 1793. [Abstract] [Full Text] [PDF]

				J. M. de la Torre Hernandez, F. Alfonso, F. Gimeno, J. A. Diarte, R. Lopez-Palop, A. Perez de Prado, F. Rivero, J. Sanchis, M. Larman, J. F. Diaz, et al. Thrombosis of Second-Generation Drug-Eluting Stents in Real Practice: Results From the Multicenter Spanish Registry ESTROFA-2 (Estudio Espanol Sobre Trombosis de Stents Farmacoactivos de Segunda Generacion-2) J. Am. Coll. Cardiol. Intv., September 1, 2010; 3(9): 911 - 919. [Abstract] [Full Text] [PDF]

				N. L. M. Cruden, S. A. Harding, A. D. Flapan, C. Graham, S. H. Wild, R. Slack, J. P. Pell, D. E. Newby, and on behalf of the Scottish Coronary Revascularisati Previous Coronary Stent Implantation and Cardiac Events in Patients Undergoing Noncardiac Surgery Circ Cardiovasc Interv, June 1, 2010; 3(3): 236 - 242. [Abstract] [Full Text] [PDF]

				F. Liistro, M. Fineschi, S. Grotti, P. Angioli, A. Carrera, K. Ducci, T. Gori, G. Falsini, C. Pierli, and L. Bolognese Long-Term Effectiveness and Safety of Sirolimus Stent Implantation for Coronary In-Stent Restenosis: Results of the TRUE (Tuscany Registry of Sirolimus for Unselected In-Stent Restenosis) Registry at 4 Years J. Am. Coll. Cardiol., February 16, 2010; 55(7): 613 - 616. [Abstract] [Full Text] [PDF]

				J. M. Lasala, D. A. Cox, D. Dobies, K. Baran, W. B. Bachinsky, E. W. Rogers, J. A. Breall, D. H. Lewis, A. Song, R. M. Starzyk, et al. Drug-Eluting Stent Thrombosis in Routine Clinical Practice: Two-Year Outcomes and Predictors From the TAXUS ARRIVE Registries Circ Cardiovasc Interv, August 1, 2009; 2(4): 285 - 293. [Abstract] [Full Text] [PDF]

				H. Samady, M. McDaniel, E. Veledar, B. De Bruyne, N. H. Pijls, W. F. Fearon, and V. Vaccarino Baseline Fractional Flow Reserve and Stent Diameter Predict Optimal Post-Stent Fractional Flow Reserve and Major Adverse Cardiac Events After Bare-Metal Stent Deployment J. Am. Coll. Cardiol. Intv., April 1, 2009; 2(4): 357 - 363. [Abstract] [Full Text] [PDF]

				M. J. Eisenberg, P. R. Richard, D. Libersan, and K. B. Filion Safety of Short-Term Discontinuation of Antiplatelet Therapy in Patients With Drug-Eluting Stents Circulation, March 31, 2009; 119(12): 1634 - 1642. [Abstract] [Full Text] [PDF]

				F. Burzotta, A. Parma, C. Pristipino, A. Manzoli, F. Belloni, G. Sardella, S. Rigattieri, A. Danesi, P. Mazzarotto, F. Summaria, et al. Angiographic and clinical outcome of invasively managed patients with thrombosed coronary bare metal or drug-eluting stents: the OPTIMIST study Eur. Heart J., December 2, 2008; 29(24): 3011 - 3021. [Abstract] [Full Text] [PDF]

				L. T. Newsome, M. A. Kutcher, and R. L. Royster Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention Anesth. Analg., August 1, 2008; 107(2): 552 - 569. [Abstract] [Full Text] [PDF]

				S. R. Dixon, C. L. Grines, and W. W. O'Neill The Year in Interventional Cardiology J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2355 - 2369. [Full Text] [PDF]

				E. Meliga, H. M. Garcia-Garcia, M. Valgimigli, A. Chieffo, G. Biondi-Zoccai, A. O. Maree, S. Cook, L. Reardon, C. Moretti, S. De Servi, et al. Longest Available Clinical Outcomes After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease: The DELFT (Drug Eluting stent for LeFT main) Registry J. Am. Coll. Cardiol., June 10, 2008; 51(23): 2212 - 2219. [Abstract] [Full Text] [PDF]

				S. Jimenez-Valero, R. Moreno, A. Sanchez-Recalde, G. Galeote, L. Calvo, A. Viana, E. Lopez de Sa, and J. Lopez-Sendon Review: Avoiding restenosis: is there a role for glucocorticoids in the drug-eluting stent era? Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 137 - 146. [Abstract] [PDF]